Stock Track | TG Therapeutics Soars 17.83% Intraday on Strong Revenue Outlook and Briumvi Sales

Stock Track

01/14

TG Therapeutics' stock surged 17.83% intraday on Wednesday, driven by the company's announcement of strong preliminary financial results for 2025 and an optimistic revenue outlook for 2026.

The biopharmaceutical company reported preliminary total global revenue of approximately $616 million for 2025, exceeding expectations, with Briumvi U.S. net product revenue reaching $594 million. For 2026, TG Therapeutics projects total global revenue of $875-900 million, including Briumvi U.S. revenue of $825-850 million, reflecting confidence in the treatment's multi-billion dollar potential.

CEO Michael Weiss highlighted Briumvi's strong commercial performance and the company's strategic initiatives to drive long-term growth, including development programs for consolidated IV dosing and a subcutaneous form of Briumvi.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1195674953"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1195674953\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1195674953?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195674953","market":"nz","top_or_hot":-1,"title":"Stock Track | TG Therapeutics Soars 17.83% Intraday on Strong Revenue Outlook and Briumvi Sales","media":"Stock Track","content":"<p>TG Therapeutics' stock surged 17.83% intraday on Wednesday, driven by the company's announcement of strong preliminary financial results for 2025 and an optimistic revenue outlook for 2026.</p><p>The biopharmaceutical company reported preliminary total global revenue of approximately $616 million for 2025, exceeding expectations, with Briumvi U.S. net product revenue reaching $594 million. For 2026, TG Therapeutics projects total global revenue of $875-900 million, including Briumvi U.S. revenue of $825-850 million, reflecting confidence in the treatment's multi-billion dollar potential.</p><p>CEO Michael Weiss highlighted Briumvi's strong commercial performance and the company's strategic initiatives to drive long-term growth, including development programs for consolidated IV dosing and a subcutaneous form of Briumvi.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TG Therapeutics Soars 17.83% Intraday on Strong Revenue Outlook and Briumvi Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TG Therapeutics Soars 17.83% Intraday on Strong Revenue Outlook and Briumvi Sales\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-01-14 22:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>TG Therapeutics' stock surged 17.83% intraday on Wednesday, driven by the company's announcement of strong preliminary financial results for 2025 and an optimistic revenue outlook for 2026.</p><p>The biopharmaceutical company reported preliminary total global revenue of approximately $616 million for 2025, exceeding expectations, with Briumvi U.S. net product revenue reaching $594 million. For 2026, TG Therapeutics projects total global revenue of $875-900 million, including Briumvi U.S. revenue of $825-850 million, reflecting confidence in the treatment's multi-billion dollar potential.</p><p>CEO Michael Weiss highlighted Briumvi's strong commercial performance and the company's strategic initiatives to drive long-term growth, including development programs for consolidated IV dosing and a subcutaneous form of Briumvi.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TGTX","symbol_name":"TG Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1195674953","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195674953","pubTimestamp":1768401283,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TG Therapeutics' stock surged 17.83% intraday on Wednesday, driven by the company's announcement of strong preliminary financial results for 2025 and an optimistic revenue outlook for 2026.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TGTX":"TG Therapeutics Inc."},"translate_title":"个股追踪|TG Therapeutics盘中大涨17.83%，营收前景强劲，Briumvi销售","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGTX":1},"content_text":"TG Therapeutics' stock surged 17.83% intraday on Wednesday, driven by the company's announcement of strong preliminary financial results for 2025 and an optimistic revenue outlook for 2026.The biopharmaceutical company reported preliminary total global revenue of approximately $616 million for 2025, exceeding expectations, with Briumvi U.S. net product revenue reaching $594 million. For 2026, TG Therapeutics projects total global revenue of $875-900 million, including Briumvi U.S. revenue of $825-850 million, reflecting confidence in the treatment's multi-billion dollar potential.CEO Michael Weiss highlighted Briumvi's strong commercial performance and the company's strategic initiatives to drive long-term growth, including development programs for consolidated IV dosing and a subcutaneous form of Briumvi.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}